Goldman Sachs Sticks to Their Buy Rating for Roche Holding AG (RHHVF)


Goldman Sachs analyst Keyur Parekh maintained a Buy rating on Roche Holding AG (RHHVF) today and set a price target of CHF441.00. The company’s shares closed last Tuesday at $338.72.

Parekh has an average return of 9.1% when recommending Roche Holding AG.

According to TipRanks.com, Parekh is ranked #3832 out of 7459 analysts.

Currently, the analyst consensus on Roche Holding AG is a Hold with an average price target of $373.41, which is a 11.0% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a CHF375.00 price target.

See today’s analyst top recommended stocks >>

Roche Holding AG’s market cap is currently $289B and has a P/E ratio of 17.90. The company has a Price to Book ratio of 17.43.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts